GE Healthcare has introduced a new range of ready-to-use systems and devices designed for biopharmaceutical production.
The ReadyToProcess portfolio is designed to meet the biopharmaceutical industry's need for increased speed, simplicity and safety for all areas of bioprocessing - from cell culture and fermentation to final purification.
The products available today with ReadyToProcess features include: single-use WAVE technologies and a set of newly-developed, ready-to-use filtration technologies; chromatography tools will be available in the near future.
ReadyToProcess technologies are said to offer considerable advantages over conventional methods used in bioprocessing, including: higher project throughput and shorter time-to-market due to the elimination of cleaning and cleaning validation steps; elimination of cross contamination problems; and reduced requirements for training and certification of employees due to the convenience of a ready-to-use format.
As the first example, the WAVE disposable technologies have provided a strong foundation for ReadyToProcess products in the market by removing hours of cleaning and preparation in cell culture, and improving the environment for gentle, consistent mixing. Meanwhile, the new filtration and chromatography offerings attack the same removal of cleaning, validation and training requirements in the downstream area.
"These are just the first steps in a long term commitment to continue the development of ReadyToProcess bioprocessing tools that enable lean production schemes and can lead the way to fully flexible manufacturing facilities," said Ann O'Hara, general manager of BioProcess at GE Healthcare Lifesciences.
"The ReadyToProcess platform will be an obvious choice for customers looking to increase early-stage project throughput and later-stage biopharmaceutical manufacturing flexibility. The growth of our ReadyToProcess products will help customers minimize the amount of time spent on preparation and changeover activities."